Innovative technique to accurately quantify live CAR-T cells in the patient, and to enable more control over cytokine release syndrome partially caused by abrupt CAR-T cell proliferation in body.
To monitor the CAR-T cells in the patient, the CAR-T cells must be labeled in some way. One method is to co-express a marker, such as the truncated extracellular domain of the epidermal growth factor receptor (EGFRt). Another method is to generate anti-CAR antibodies or soluble recombinant ligands, which bind to the single-chain antibody fragment (scFv). We developed a more direct method for CAR-T cells tracking by attaching a Beacon domain directly to the CAR. In vitro and in vivo research proved that BeaconTM technology allows us to accurately detect live CAR-T cells in the patient and to control CAR-T toxicity without diminishing the efficacy.